• About
    • Corporate Overview
    • Management Team
    • Scientific Advisory Committee
    • Partnerships
    • Compliance and ethics
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
  • Medical Information
    • Publications & Presentations
    • Medical Grants – IST
    • Medical Grants – CME
    • Expanded Access Policy
    • Contact Medical Information
  • Media
    • Press Releases
    • Media Toolkit
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

© 2012 AVEO Pharmaceuticals, Inc. All rights reserved.
Terms of Use Privacy Policy Cookie Notice Code of Business Conduct and Ethics
MENU logo
  • About
    • Corporate Overview
    • Management Team
    • Scientific Advisory Committee
    • Partnerships
    • Compliance and ethics
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
  • Medical Information
    • Publications & Presentations
    • Medical Grants – IST
    • Medical Grants – CME
    • Expanded Access Policy
    • Contact Medical Information
  • Media
    • Press Releases
    • Media Toolkit
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact